Addiction as a brain disease revised: why it still matters, and the need for consilience.


Journal

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907

Informations de publication

Date de publication:
09 2021
Historique:
received: 10 11 2020
accepted: 14 12 2020
revised: 11 12 2020
pubmed: 24 2 2021
medline: 28 8 2021
entrez: 23 2 2021
Statut: ppublish

Résumé

The view that substance addiction is a brain disease, although widely accepted in the neuroscience community, has become subject to acerbic criticism in recent years. These criticisms state that the brain disease view is deterministic, fails to account for heterogeneity in remission and recovery, places too much emphasis on a compulsive dimension of addiction, and that a specific neural signature of addiction has not been identified. We acknowledge that some of these criticisms have merit, but assert that the foundational premise that addiction has a neurobiological basis is fundamentally sound. We also emphasize that denying that addiction is a brain disease is a harmful standpoint since it contributes to reducing access to healthcare and treatment, the consequences of which are catastrophic. Here, we therefore address these criticisms, and in doing so provide a contemporary update of the brain disease view of addiction. We provide arguments to support this view, discuss why apparently spontaneous remission does not negate it, and how seemingly compulsive behaviors can co-exist with the sensitivity to alternative reinforcement in addiction. Most importantly, we argue that the brain is the biological substrate from which both addiction and the capacity for behavior change arise, arguing for an intensified neuroscientific study of recovery. More broadly, we propose that these disagreements reveal the need for multidisciplinary research that integrates neuroscientific, behavioral, clinical, and sociocultural perspectives.

Identifiants

pubmed: 33619327
doi: 10.1038/s41386-020-00950-y
pii: 10.1038/s41386-020-00950-y
pmc: PMC8357831
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1715-1723

Subventions

Organisme : NIDA NIH HHS
ID : K24 DA050087
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

© 2021. The Author(s).

Références

Leshner AI. Addiction is a brain disease, and it matters. Science. 1997;278:45–7.
pubmed: 9311924 doi: 10.1126/science.278.5335.45
McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689–95.
pubmed: 11015800 doi: 10.1001/jama.284.13.1689
Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG, Angermeyer MC. The stigma of alcohol dependence compared with other mental disorders: a review of population studies. Alcohol Alcohol. 2011;46:105–12.
pubmed: 21169612 doi: 10.1093/alcalc/agq089
Heyman GM. Addiction and choice: theory and new data. Front Psychiatry. 2013;4:31.
pubmed: 23653607 pmcid: 3644798 doi: 10.3389/fpsyt.2013.00031
Heather N, Best D, Kawalek A, Field M, Lewis M, Rotgers F, et al. Challenging the brain disease model of addiction: European launch of the addiction theory network. Addict Res Theory. 2018;26:249–55.
doi: 10.1080/16066359.2017.1399659
Pickard H, Ahmed SH, Foddy B. Alternative models of addiction. Front Psychiatr.y 2015;6:20.
Hall W, Carter A, Forlini C. The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises? Lancet Psychiatr. 2015;2:105–10.
doi: 10.1016/S2215-0366(14)00126-6
Hart CL. Viewing addiction as a brain disease promotes social injustice. Nat Hum Behav. 2017;1:0055.
doi: 10.1038/s41562-017-0055
Heilig M, Epstein DH, Nader MA, Shaham Y. Time to connect: bringing social context into addiction neuroscience. Nat Rev Neurosc.i 2016;17:592–9.
doi: 10.1038/nrn.2016.67
Jellinek EM. The disease concept of alcoholism. Hillhouse Press on behalf of the Christopher J. Smithers Foundation: New Haven, CT; 1960.
Stevenson A. Oxford dictionary of English. 3 ed. New York, NY: Oxford University Press; 2010.
Fan J, May SJ, Zhou Y, Barrett-Connor E. Bimodality of 2-h plasma glucose distributions in whites: the Rancho Bernardo study. Diabetes Care 2005;28:1451–6.
pubmed: 15920067 doi: 10.2337/diacare.28.6.1451
King AC, Vena A, Hasin D, De Wit D, O’Connor CJ, Cao D. Subjective responses to alcohol in the development and maintenance of alcohol use disorder (AUD). Am J Psychiatry. 2021. https://doi.org/10.1176/appi.ajp.2020.20030247 .
GBD. 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5:987–1012.
doi: 10.1016/S2215-0366(18)30337-7
Edwards G, Gross MM. Alcohol dependence: provisional description of a clinical syndrome. Br Med J. 1976;1:1058–61.
pubmed: 773501 pmcid: 1639901 doi: 10.1136/bmj.1.6017.1058
Epstein DH, Heilig M, Shaham Y. Science-based actions can help address the opioid crisis. Trends Pharm Sci. 2018;39:911–16.
pubmed: 30343726 doi: 10.1016/j.tips.2018.06.002
Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abus Treat. 2005;28:321–9.
doi: 10.1016/j.jsat.2005.02.007
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Datab System Rev. 2013;5:CD009329.
Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings a systematic review and meta-analysis. JAMA. 2014;311:1889–900.
pubmed: 24825644 doi: 10.1001/jama.2014.3628
Mark TL, Kranzler HR, Song X. Understanding US addiction physicians’ low rate of naltrexone prescription. Drug Alcohol Depend. 2003;71:219–28.
pubmed: 12957340 doi: 10.1016/S0376-8716(03)00134-0
Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376:1558–65.
pubmed: 21036393 doi: 10.1016/S0140-6736(10)61462-6
Wilk AI, Jensen NM, Havighurst TC. Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. J Gen Intern Med. 1997;12:274–83.
pubmed: 9159696 pmcid: 1497107 doi: 10.1007/s11606-006-5063-z
Laing RD. The divided self; a study of sanity and madness. London: Tavistock Publications; 1960.
Foucault M, Khalfa J. History of madness. New York: Routledge; 2006.
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL. et al.Comorbidity of mental disorders with alcohol and other drug abuse. Results Epidemiologic Catchment Area (ECA) study.JAMA. 1990;264:2511–8.
pubmed: 2232018 doi: 10.1001/jama.1990.03450190043026
Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807–16.
pubmed: 15289279 doi: 10.1001/archpsyc.61.8.807
Lopez-Quintero C, Hasin DS, de Los Cobos JP, Pines A, Wang S, Grant BF, et al. Probability and predictors of remission from life-time nicotine, alcohol, cannabis or cocaine dependence: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Addiction. 2011;106:657–69.
pubmed: 21077975 doi: 10.1111/j.1360-0443.2010.03194.x
Humphreys K. Addiction treatment professionals are not the gatekeepers of recovery. Subst Use Misuse. 2015;50:1024–7.
pubmed: 25774891 pmcid: 4821402 doi: 10.3109/10826084.2015.1007678
Cohen E, Feinn R, Arias A, Kranzler HR. Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2007;86:214–21.
pubmed: 16919401 doi: 10.1016/j.drugalcdep.2006.06.008
Sobell LC, Cunningham JA, Sobell MB. Recovery from alcohol problems with and without treatment: prevalence in two population surveys. Am J Public Health. 1996;86:966–72.
pubmed: 8669520 pmcid: 1380437 doi: 10.2105/AJPH.86.7.966
Culverhouse R, Bucholz KK, Crowe RR, Hesselbrock V, Nurnberger JI Jr, Porjesz B, et al. Long-term stability of alcohol and other substance dependence diagnoses and habitual smoking: an evaluation after 5 years. Arch Gen Psychiatry. 2005;62:753–60.
pubmed: 15997016 doi: 10.1001/archpsyc.62.7.753
Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64:830–42.
pubmed: 17606817 doi: 10.1001/archpsyc.64.7.830
Skolnick P. The opioid epidemic: crisis and solutions. Annu Rev Pharm Toxicol. 2018;58:143–59.
doi: 10.1146/annurev-pharmtox-010617-052534
Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015;23:76–89.
pubmed: 25747921 doi: 10.1097/HRP.0000000000000052
Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91:102–23.
pubmed: 23554523 pmcid: 3605003 doi: 10.2471/BLT.12.108282
Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72:757–66.
pubmed: 26039070 pmcid: 5240584 doi: 10.1001/jamapsychiatry.2015.0584
Lee MR, Sher KJ. “Maturing Out” of binge and problem drinking. Alcohol Res: Curr Rev. 2018;39:31–42.
Dawson DA, Grant BF, Stinson FS, Chou PS, Huang B, Ruan WJ. Recovery from DSM-IV alcohol dependence: United States, 2001–2002. Addiction. 2005;100:281–92.
pubmed: 15733237 doi: 10.1111/j.1360-0443.2004.00964.x
Berridge V. The rise, fall, and revival of recovery in drug policy. Lancet. 2012;379:22–23.
pubmed: 22232800 doi: 10.1016/S0140-6736(12)60011-7
Parvaz MA, Moeller SJ, d’Oleire Uquillas F, Pflumm A, Maloney T, Alia-Klein N, et al. Prefrontal gray matter volume recovery in treatment-seeking cocaine-addicted individuals: a longitudinal study. Addict Biol. 2017;22:1391–401.
pubmed: 27126701 doi: 10.1111/adb.12403
Korponay C, Kosson DS, Decety J, Kiehl KA, Koenigs M. Brain volume correlates with duration of abstinence from substance abuse in a region-specific and substance-specific manner. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017;2:626–35.
pubmed: 29308437 pmcid: 5749429
Janes AC, Datko M, Roy A, Barton B, Druker S, Neal C, et al. Quitting starts in the brain: a randomized controlled trial of app-based mindfulness shows decreases in neural responses to smoking cues that predict reductions in smoking. Neuropsychopharmacology. 2019;44:1631–38.
pubmed: 31039580 pmcid: 6785102 doi: 10.1038/s41386-019-0403-y
Humphreys K, Bickel WK. Toward a neuroscience of long-term recovery from addiction. JAMA Psychiatry. 2018;75:875–76.
pubmed: 29847627 doi: 10.1001/jamapsychiatry.2018.0956
Verhulst B, Neale MC, Kendler KS. The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies. Psychol Med. 2015;45:1061–72.
pubmed: 25171596 doi: 10.1017/S0033291714002165
Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet. 2005;6:521–32.
pubmed: 15995696 doi: 10.1038/nrg1635
Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. AJ Psychiatry. 2003;160:687–95.
Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.
doi: 10.1038/nature13595
Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–81.
pubmed: 29700475 pmcid: 5934326 doi: 10.1038/s41588-018-0090-3
Wray NR, Lin T, Austin J, McGrath JJ, Hickie IB, Murray GK, et al. From basic science to clinical application of polygenic risk scores: a primer. JAMA Psychiatry. 2021;78:101–9.
pubmed: 32997097 doi: 10.1001/jamapsychiatry.2020.3049
Walters RK, Polimanti R, Johnson EC, McClintick JN, Adams MJ, Adkins AE, et al. Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. Nat Neurosci. 2018;21:1656–69.
pubmed: 30482948 pmcid: 6430207 doi: 10.1038/s41593-018-0275-1
Visscher PM, Wray NR. Concepts and misconceptions about the polygenic additive model applied to disease. Hum Hered. 2015;80:165–70.
pubmed: 27576756 doi: 10.1159/000446931
Heilig M, Leggio L. What the alcohol doctor ordered from the neuroscientist: theragnostic biomarkers for personalized treatments. Prog Brain Res. 2016;224:401–18.
pubmed: 26822368 doi: 10.1016/bs.pbr.2015.07.023
Rasmussen K, White DA, Acri JB. NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology. 2019;44:657–59.
pubmed: 30538289 doi: 10.1038/s41386-018-0292-5
Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. AJ Psychiatry. 2010;167:748–51.
Kwako LE, Schwandt ML, Ramchandani VA, Diazgranados N, Koob GF, Volkow ND, et al. Neurofunctional domains derived from deep behavioral phenotyping in alcohol use disorder. AJ Psychiatry. 2019;176:744–53.
Kwako LE, Bickel WK, Goldman D. Addiction biomarkers: dimensional approaches to understanding addiction. Trends Mol Med. 2018;24:121–28.
pubmed: 29307501 pmcid: 6233300 doi: 10.1016/j.molmed.2017.12.007
Xiao P, Dai Z, Zhong J, Zhu Y, Shi H, Pan P. Regional gray matter deficits in alcohol dependence: a meta-analysis of voxel-based morphometry studies. Drug Alcohol Depend. 2015;153:22–8.
pubmed: 26072220 doi: 10.1016/j.drugalcdep.2015.05.030
Ersche KD, Williams GB, Robbins TW, Bullmore ET. Meta-analysis of structural brain abnormalities associated with stimulant drug dependence and neuroimaging of addiction vulnerability and resilience. Curr Opin Neurobiol. 2013;23:615–24.
pubmed: 23523373 doi: 10.1016/j.conb.2013.02.017
Klugah-Brown B, Di X, Zweerings J, Mathiak K, Becker B, Biswal B. Common and separable neural alterations in substance use disorders: a coordinate-based meta-analyses of functional neuroimaging studies in humans. Hum Brain Mapp. 2020;41:4459–77.
pubmed: 32964613 pmcid: 7555084 doi: 10.1002/hbm.25085
Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights from imaging studies. J Clin Investig. 2003;111:1444–51.
pubmed: 12750391 pmcid: 155054 doi: 10.1172/JCI18533
Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011;12:652–69.
pubmed: 22011681 pmcid: 3462342 doi: 10.1038/nrn3119
Goodkind M, Eickhoff SB, Oathes DJ, Jiang Y, Chang A, Jones-Hagata LB, et al. Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry. 2015;72:305–15.
pubmed: 25651064 pmcid: 4791058 doi: 10.1001/jamapsychiatry.2014.2206
Scofield MD, Heinsbroek JA, Gipson CD, Kupchik YM, Spencer S, Smith AC, et al. The nucleus accumbens: mechanisms of addiction across drug classes reflect the importance of glutamate homeostasis. Pharm Rev. 2016;68:816–71.
pubmed: 27363441 pmcid: 4931870 doi: 10.1124/pr.116.012484
Korpi ER, den Hollander B, Farooq U, Vashchinkina E, Rajkumar R, Nutt DJ, et al. Mechanisms of action and persistent neuroplasticity by drugs of abuse. Pharm Rev. 2015;67:872–1004.
pubmed: 26403687 doi: 10.1124/pr.115.010967
Luscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron. 2011;69:650–63.
pubmed: 21338877 pmcid: 4046255 doi: 10.1016/j.neuron.2011.01.017
Everitt BJ. Neural and psychological mechanisms underlying compulsive drug seeking habits and drug memories–indications for novel treatments of addiction. Eur J Neurosci. 2014;40:2163–82.
pubmed: 24935353 pmcid: 4145664 doi: 10.1111/ejn.12644
Lesscher HM, Vanderschuren LJ. Compulsive drug use and its neural substrates. Rev Neurosci. 2012;23:731–45.
pubmed: 23079511 doi: 10.1515/revneuro-2012-0066
Cruz FC, Koya E, Guez-Barber DH, Bossert JM, Lupica CR, Shaham Y, et al. New technologies for examining the role of neuronal ensembles in drug addiction and fear. Nat Rev Neurosci. 2013;14:743–54.
pubmed: 24088811 pmcid: 4530016 doi: 10.1038/nrn3597
Crick F. The astonishing hypothesis: the scientific search for the soul. Scribner; Maxwell Macmillan International: New York, NY; 1994.
Vanderschuren LJ, Achterberg EJ, Trezza V. The neurobiology of social play and its rewarding value in rats. Neurosci Biobehav Rev. 2016;70:86–105.
pubmed: 27587003 pmcid: 5074863 doi: 10.1016/j.neubiorev.2016.07.025
Venniro M, Zhang M, Caprioli D, Hoots JK, Golden SA, Heins C, et al. Volitional social interaction prevents drug addiction in rat models. Nat Neurosci. 2018;21:1520–29.
pubmed: 30323276 pmcid: 7386559 doi: 10.1038/s41593-018-0246-6
Martinez D, Orlowska D, Narendran R, Slifstein M, Liu F, Kumar D, et al. Dopamine type 2/3 receptor availability in the striatum and social status in human volunteers. Biol Psychiatry. 2010;67:275–8.
pubmed: 19811777 doi: 10.1016/j.biopsych.2009.07.037
Wiers CE, Shokri-Kojori E, Cabrera E, Cunningham S, Wong C, Tomasi D, et al. Socioeconomic status is associated with striatal dopamine D2/D3 receptors in healthy volunteers but not in cocaine abusers. Neurosci Lett. 2016;617:27–31.
pubmed: 26828302 pmcid: 4798870 doi: 10.1016/j.neulet.2016.01.056
Morgan D, Grant KA, Gage HD, Mach RH, Kaplan JR, Prioleau O, et al. Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nat Neurosci. 2002;5:169–74.
pubmed: 11802171 doi: 10.1038/nn798
Hughes K, Bellis MA, Hardcastle KA, Sethi D, Butchart A, Mikton C, et al. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. Lancet Public Health. 2017;2:e356–e66.
pubmed: 29253477 doi: 10.1016/S2468-2667(17)30118-4
Gilbert PA, Zemore SE. Discrimination and drinking: a systematic review of the evidence. Soc Sci Med 2016;161:178–94.
pubmed: 27315370 pmcid: 4921286 doi: 10.1016/j.socscimed.2016.06.009
Oshri A, Gray JC, Owens MM, Liu S, Duprey EB, Sweet LH, et al. Adverse childhood experiences and amygdalar reduction: high-resolution segmentation reveals associations with subnuclei and psychiatric outcomes. Child Maltreat. 2019;24:400–10.
pubmed: 31030539 pmcid: 6813855 doi: 10.1177/1077559519839491
Holmes CJ, Barton AW, MacKillop J, Galván A, Owens MM, McCormick MJ, et al. Parenting and salience network connectivity among African Americans: a protective pathway for health-risk behaviors. Biol Psychiatry. 2018;84:365–71.
pubmed: 29731104 pmcid: 6097936 doi: 10.1016/j.biopsych.2018.03.003
Brody GH, Gray JC, Yu T, Barton AW, Beach SR, Galván A, et al. Protective prevention effects on the association of poverty with brain development. JAMA Pediatr. 2017;171:46–52.
pubmed: 27893880 pmcid: 5214580 doi: 10.1001/jamapediatrics.2016.2988
Hanson JL, Gillmore AD, Yu T, Holmes CJ, Hallowell ES, Barton AW, et al. A family focused intervention influences hippocampal-prefrontal connectivity through gains in self-regulation. Child Dev. 2019;90:1389–401.
pubmed: 30295319 doi: 10.1111/cdev.13154
Borsboom D, Cramer A, Kalis A. Brain disorders? Not really… why network structures block reductionism in psychopathology research. Behav Brain Sci. 2018;42:1–54.
Field M, Heather N, Wiers RW. Indeed, not really a brain disorder: Implications for reductionist accounts of addiction. Behav Brain Sci. 2019;42:e9.
pubmed: 30940232 doi: 10.1017/S0140525X18001024
Pascoli V, Hiver A, Van Zessen R, Loureiro M, Achargui R, Harada M, et al. Stochastic synaptic plasticity underlying compulsion in a model of addiction. Nature. 2018;564:366–71.
pubmed: 30568192 doi: 10.1038/s41586-018-0789-4
James W. The dilemma of determinism. Whitefish, MT: Kessinger Publishing; 2005.
Gessell B. Indeterminism in the brain. Biol Philos. 2017;32:1205–23.
doi: 10.1007/s10539-017-9601-3
Jedlicka P. Revisiting the quantum brain hypothesis: toward quantum (neuro)biology? Front Mol Neurosci. 2017;10:366.
pubmed: 29163041 pmcid: 5681944 doi: 10.3389/fnmol.2017.00366
Heyman GM. Addiction: a disorder of choice. Cambridge, MA: Harvard University Press; 2010.
Heather NQ. Is addiction a brain disease or a moral failing? A: Neither. Neuroethics. 2017;10:115–24.
pubmed: 28725283 pmcid: 5486515 doi: 10.1007/s12152-016-9289-0
Ahmed SH, Lenoir M, Guillem K. Neurobiology of addiction versus drug use driven by lack of choice. Curr Opin Neurobiol. 2013;23:581–7.
pubmed: 23428657 doi: 10.1016/j.conb.2013.01.028
Hogarth L, Lam-Cassettari C, Pacitti H, Currah T, Mahlberg J, Hartley L, et al. Intact goal-directed control in treatment-seeking drug users indexed by outcome-devaluation and Pavlovian to instrumental transfer: critique of habit theory. Eur J Neurosci. 2019;50:2513–25.
pubmed: 29787620 doi: 10.1111/ejn.13961
Mathis V, Kenny PJ. From controlled to compulsive drug-taking: the role of the habenula in addiction. Neurosci Biobehav Rev. 2019;106:102–11.
pubmed: 29936111 doi: 10.1016/j.neubiorev.2018.06.018
Luscher C, Robbins TW, Everitt BJ. The transition to compulsion in addiction. Nat Rev Neurosci. 2020;21:247–63.
pubmed: 32231315 pmcid: 7610550 doi: 10.1038/s41583-020-0289-z
Robinson TE, Berridge KC. Addiction. Annu Rev Psychol. 2003;54:25–53.
pubmed: 12185211 doi: 10.1146/annurev.psych.54.101601.145237
Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005;8:1481–89.
pubmed: 16251991 doi: 10.1038/nn1579
Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35:217–38.
pubmed: 19710631 doi: 10.1038/npp.2009.110
Tiffany ST. A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes. Psychol Rev. 1990;97:147–68.
pubmed: 2186423 doi: 10.1037/0033-295X.97.2.147
Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev. 1993;18:247–91.
pubmed: 8401595 doi: 10.1016/0165-0173(93)90013-P
Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. Nat Neurosci. 2005;8:1442–4.
pubmed: 16251985 doi: 10.1038/nn1105-1442
Stein DJ, Costa DLC, Lochner C, Miguel EC, Reddy YCJ, Shavitt RG, et al. Obsessive-compulsive disorder. Nat Rev Dis Prim. 2019;5:52.
pubmed: 31371720 doi: 10.1038/s41572-019-0102-3
Vanderschuren LJ, Everitt BJ. Drug seeking becomes compulsive after prolonged cocaine self-administration. Science 2004;305:1017–9.
pubmed: 15310907 doi: 10.1126/science.1098975
American_Psychiatric_Association. Diagnostic and statistical manual of mental disorders: DSM-5™. 5th ed. Arlington, VA, US: American Psychiatric Publishing, Inc; 2013.
doi: 10.1176/appi.books.9780890425596
Spragg SDS. Morphine addiction in chimpanzees. Comp Psychol Monogr. 1940;15:132–32.
Lenoir M, Cantin L, Vanhille N, Serre F, Ahmed SH. Extended heroin access increases heroin choices over a potent nondrug alternative. Neuropsychopharmacology. 2013;38:1209–20.
pubmed: 23322185 pmcid: 3656363 doi: 10.1038/npp.2013.17
Caprioli D, Venniro M, Zeric T, Li X, Adhikary S, Madangopal R, et al. Effect of the novel positive allosteric modulator of metabotropic glutamate receptor 2 AZD8529 on incubation of methamphetamine craving after prolonged voluntary abstinence in a rat model. Biol Psychiatry. 2015;78:463–73.
pubmed: 25861699 pmcid: 4546920 doi: 10.1016/j.biopsych.2015.02.018
Augier E, Barbier E, Dulman RS, Licheri V, Augier G, Domi E, et al. A molecular mechanism for choosing alcohol over an alternative reward. Science. 2018;360:1321–26.
pubmed: 29930131 doi: 10.1126/science.aao1157
Bigelow GE. An operant behavioral perspective on alcohol abuse and dependence. In: Heather N, Peters TJ, Stockwell T, editors. International handbook of alcohol dependence and problems. John Wiley & Sons Ltd; 2001. p. 299–315.
Higgins ST, Heil SH, Lussier JP. Clinical implications of reinforcement as a determinant of substance use disorders. Annu Rev Psychol. 2004;55:431–61.
pubmed: 14744222 doi: 10.1146/annurev.psych.55.090902.142033
Satel S, Lilienfeld SO. Brainwashed: the seductive appeal of mindless neuroscience. New York, NY: Basic Books; 2015.
Wilson EO. Consilience: the unity of knowledge. New York, NY: Vintage Books; 1999.
Saunders JB, Degenhardt L, Reed GM, Poznyak V. Alcohol use disorders in ICD-11: past, present, and future. Alcohol Clin Exp Res 2019;43:1617–31.
pubmed: 31194891 doi: 10.1111/acer.14128
Organization. WH. ICD-11 for mortality and morbidity statistics. 2018. https://icd.who.int/browse11/l-m/en . Accessed 21 Oct 2020.
Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, brief intervention, and referral to treatment (SBIRT): toward a public health approach to the management of substance abuse. Subst Abus. 2007;28:7–30.
pubmed: 18077300 doi: 10.1300/J465v28n03_03
Witkiewitz K, Hallgren KA, Kranzler HR, Mann KF, Hasin DS, Falk DE, et al. Clinical validation of reduced alcohol consumption after treatment for alcohol dependence using the World Health Organization risk drinking levels. Alcohol Clin Exp Res 2017;41:179–86.
pubmed: 28019652 doi: 10.1111/acer.13272
Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. AJ Psychiatry. 2013;170:834–51.
Rosenthal RJ, Faris SB. The etymology and early history of ‘addiction’. Addict Res Theory. 2019;27:437–49.
doi: 10.1080/16066359.2018.1543412
Martin CS, Steinley DL, Verges A, Sher KJ. The proposed 2/11 symptom algorithm for DSM-5 substance-use disorders is too lenient. Psychol Med. 2011;41:2008–10.
pubmed: 21557890 pmcid: 4245011 doi: 10.1017/S0033291711000717
Degenhardt L, Bharat C, Bruno R, Glantz MD, Sampson NA, Lago L, et al. Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHO’s World Mental Health Surveys. Addiction. 2019;114:534–52.
pubmed: 30370636
Lago L, Bruno R, Degenhardt L. Concordance of ICD-11 and DSM-5 definitions of alcohol and cannabis use disorders: a population survey. Lancet Psychiatry. 2016;3:673–84.
pubmed: 27371989 doi: 10.1016/S2215-0366(16)00088-2
Lundin A, Hallgren M, Forsman M, Forsell Y. Comparison of DSM-5 classifications of alcohol use disorders with those of DSM-IV, DSM-III-R, and ICD-10 in a general population sample in Sweden. J Stud Alcohol Drugs. 2015;76:773–80.
pubmed: 26402358 doi: 10.15288/jsad.2015.76.773
Kwako LE, Momenan R, Litten RZ, Koob GF, Goldman D. Addictions neuroclinical assessment: a neuroscience-based framework for addictive disorders. Biol Psychiatry. 2016;80:179–89.
pubmed: 26772405 doi: 10.1016/j.biopsych.2015.10.024
Rehm J, Heilig M, Gual A. ICD-11 for alcohol use disorders: not a convincing answer to the challenges. Alcohol Clin Exp Res. 2019;43:2296–300.
pubmed: 31424579 pmcid: 6899584 doi: 10.1111/acer.14182

Auteurs

Markus Heilig (M)

Center for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. markus.heilig@liu.se.

James MacKillop (J)

Peter Boris Centre for Addictions Research, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Homewood Research Institute, Guelph, ON, Canada.

Diana Martinez (D)

New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, NY, USA.

Jürgen Rehm (J)

Institute for Mental Health Policy Research & Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.
Dalla Lana School of Public Health and Department of Psychiatry, University of Toronto (UofT), Toronto, ON, Canada.
Klinische Psychologie & Psychotherapie, Technische Universität Dresden, Dresden, Germany.
Department of International Health Projects, Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.

Lorenzo Leggio (L)

Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, MD, USA.

Louk J M J Vanderschuren (LJMJ)

Department of Population Health Sciences, Unit Animals in Science and Society, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH